We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

CDER New Drug Reviews Are At 80%-90% Of User Fee Goals, Jenkins Says

News

Executive Summary

The Center for Drug Evaluation and Research's performance in reviewing applications for new drugs and biologics within the timelines specified by the Prescription Drug User Fee Act has slipped to 80 percent to 90 percent